Immunologic Factor – Page 37

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

11 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply

11 months ago talkbio0Tagged BARDA, bird flu vaccine, CSHL1 gene, public health medicine (field), sanofi, SmithKline Beecham, Vaccines

BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health

Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal

11 months ago talkbio0Tagged Cold Hemagglutinin Disease, Enjaymo, pharmaceutical acquisition, Recordati, sanofi

Recordati, Sanofi, Enjaymo, rare disease, cold agglutinin disease (CAD), pharmaceutical acquisition

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

11 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer

12 months ago talkbio0Tagged Cancer Vaccines, ctDNA, granite, Gritstone Bio, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, MSS-CRC, Neoantigen, Progression-Free Survival

Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

12 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses